drugset / Trial / NCT01152996

Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study

NCT01152996

Phase 3 Completed 1075 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.

Timeline

Start
2010-09
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vortioxetine Unknown 15 mg Oral
Subject Vortioxetine Unknown 20 mg Oral